Cognitive decline and disease progression in different neurodegenerative diseases typically involves synaptic dysfunction preceding the neuronal loss. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
In mature neurons, the number of synapses is determined by a neuronal activity-dependent dynamic equilibrium between positive and negative regulatory factors. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
One of the shared hallmarks of neurodegenerative diseases is the accumulation of misfolded proteins. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Proteostasis are integrated biological pathways within cells that control synthesis, folding, trafficking and degradation of proteins. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The extracellular aggregation of proteins into proteotoxic oligomers and amyloid fibrils is implicated in the onset and pathology of numerous diseases referred to as amyloid diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Family caregivers of patients with frontotemporal dementia identify behavioral disturbances as most troubling. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Case management for persons with dementia may increase use of community-based services and delay nursing home admission. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Advance care planning is the basis for delivering person-centred end of life care that accords with the wishes of the individual. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This paper will highlight some of the pertinent issues associated with palliative and end-of-life decision-making in relation to dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hospice use over 2 weeks was associated with decreased hospital days (1-5 days overall, with greater decreases for longer hospice use) for all beneficiaries; spending was $900-$5,000 less for hospice use of 31-90 days for most beneficiaries not in nursing homes, except beneficiaries with Alzheimer's. Overall spending decreased with hospice use for beneficiaries in nursing homes with lung cancer only, with a $3,500 reduction. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Adjunctive florbetapir-PET increased quality-adjusted life years (QALYs) by 0.008 years and increased costs by 36 compared to SCE alone (incremental cost-effectiveness ratio [ICER], 4,769). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma SAH levels and atherosclerotic lesion size were significantly increased in adenosine dialdehyde and SAH hydrolase short hairpin RNA groups when compared with control group. 5 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
This widely cited review examined the long-running debate over whether amyloid or tau comes first in Alzheimer's disease. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
We previously reported that, in the brains of older patients with vascular dementia (VaD), there is a distinctive accumulation of detergent-extractable soluble amyloid-β, with a predominance of Aβ42 species. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Endothelial degeneration and preservation of basement membrane result in an increase of string vessel formation in PD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
36/100
In a perimenopausal model of middle-aged rats, the astrocyte estrogen receptor-alpha (ERa): ER-beta (ERb) ratio increased with the onset of acyclicity (constant estrus, CE) in association with impaired neurotrophic responses to estradiol (E2). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The association of generalized epilepsy with elderly DS represents an epiphenomenon in evolution which is associated with a progressive deterioration of cognitive and motor functions. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neurosyphilis is a neurological disease that involves infection of the central nervous system with Treponema pallidum. 4 key findings →
Participants: 44 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Biomarkers in the cerebrospinal fluid (CSF) are currently regarded as indispensable indicators for accurate differential diagnosis of neurodegenerative disorders. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common senile dementia in the world. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Receptor for advanced glycation end products (RAGE) is a receptor of the immunoglobulin super family that plays various important roles under physiological and pathological conditions. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Pathological tau leads to dementia and neurodegeneration in tauopathies, including Alzheimer's disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
This article presents an update on the clinical aspects of human prion disease, including the wide spectrum of their presentations. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Tauopathies are a class of neurodegenerative disorders characterized by neuronal and/or glial inclusions composed of the microtubule-binding protein, tau. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Therapeutic attempts to cure Alzheimer's disease (AD) have failed, and new strategies are desperately needed. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →